Humanized CD19-targeted chimeric antigen receptor T (CAR-T) cells for relapsed/refractory pediatric acute lymphoblastic leukemia

Am J Hematol. 2021 May 1;96(5):E162-E165. doi: 10.1002/ajh.26123. Epub 2021 Feb 21.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Animals
  • Antibodies, Monoclonal, Humanized / immunology
  • Antigens, CD19 / immunology*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Child
  • Child, Preschool
  • Combined Modality Therapy
  • Female
  • Follow-Up Studies
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Immunotherapy, Adoptive*
  • Kaplan-Meier Estimate
  • Male
  • Mice
  • Pilot Projects
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy*
  • Remission Induction
  • Salvage Therapy*
  • Single-Chain Antibodies / immunology
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Antigens, CD19
  • CD19 molecule, human
  • Single-Chain Antibodies